Khalid Al Sulaiman, MBA, BCCCP, , BCNSP
Consultant, Critical Care Clinical Pharmacist
King Abdulaziz Medical City, Riyadh, Saudi Arabia
Riyadh, Saudi Arabia
Disclosure information not submitted.
Ioana Antonescu, MD, MSc
n/a
Raleigh, North Carolina, United States
Disclosure information not submitted.
Ghazwa B. Korayem, Pharma D.
Assistant Professor
Princess Nora bint Abdulrahman University, Saudi Arabia
Disclosure information not submitted.
Ali Altebainawi
Clinical Pharmacist
King Khalid Hospital, Saudi Arabia
Disclosure information not submitted.
Abdulrahman Al Shaya, Pharma D., BCCCP
Critical Care Clinical Pharmacist
King Abdulaziz Medical City, Saudi Arabia
Disclosure information not submitted.
Hisham Badreldin, Pharma D., FCCP
Cardiology, Clinical Pharmacist
King Abdulaziz Medical City, Saudi Arabia
Disclosure information not submitted.
Abdullah Al Harthi, n/a
Critical Care Clinical Pharmacist
King Abdulaziz Medical City, Senegal
Disclosure information not submitted.
Abdulrahman Alissa
Critical Care Clinical Pharmacist
King Abdullah bin Abdulaziz University Hospital, Saudi Arabia
Disclosure information not submitted.
Ramesh Vishwakarma, PhD statistics
Research Biostatistician
King Abdullah International Medical Research Center, Saudi Arabia
Disclosure information not submitted.
Raed Kensara
Critical Care Clinical Pharmacist
King Abdulaziz Medical City, Saudi Arabia
Disclosure information not submitted.
Title: Impact of statins on the clinical outcomes in COVID-19 critically ill patients: A Multicenter Study
Background: Severe Corona Virus Disease 2019 (COVID-19) can heighten the systematic inflammatory response in critically ill patients, causing a systemic hyperinflammatory state leading to multiple complications. Statins can potentially be a potent adjuvant therapy in COVID-19 infection due to pleiotropic effects; it exerts anti-inflammatory actions independent of their cholesterol-lowering effects. This study investigates the impact of statin use on the outcome of critically ill patients with COVID-19.
Method: A multicenter, retrospective cohort study for all adult critically ill patients with confirmed COVID-19 admitted to Intensive Care Units (ICUs) between March 1, 2020, and January 31, 2021. The primary outcome was to evaluate statin use in COVID-19 critically ill patients and its association with mortality; other outcomes were considered secondary. Eligible patients were classified into two groups based on statin use during ICU stay. Propensity score-matched used based on patient's age, APACHE 2, and SOFA score within 24 hours of ICU admission. We considered a P value of < 0.05 statistically significant.
Results: A total of 1049 patients were eligible; 502 patients were included after propensity score matching (1:1 ratio). The 30-day (HR (95%CI): 0.75 (0.58, 0.98), p-value=0.03) and in-hospital mortality (HR (95%CI): 0.69 (0.54, 0.89), p-value=0.004) were statistically significant lower in patients who received statin therapy. Moreover, patients who received statin have a lower odd of hospital acquired pneumonia (OR (95%CI): 0.48(0.32, 0.69), p-value=< 0.001). On the other hand, secondary fungal infection was higher (OR (95%CI): 2.48(1.44, 4.24), p-value=0.001)
Conclusion: The use of statin as adjunctive therapy in COVID-19 critically ill patients may have a beneficial role and survival benefits with a good safety profile.